Veeva Systems Inc.’s Vault EDC has hit a milestone, igniting over 1,000 study initiations. The surge in adoption speaks volumes about the traction of Vault EDC, providing a springboard for contemporary electronic data capture practices. This includes eight biopharmas and two contract research organizations (CROs) entrusting Vault EDC as a standard.
Vault EDC, structured in Veeva Vault Clinical Data Management, merges EDC with Veeva Clinical Database for pioneering clinical data management.
The recent success of Veeva Vault EDC in igniting numerous studies is poised to invigorate Veeva Vault Clinical Data Management operations.
The Central Role of Adoption
The escalating adoption of Vault EDC underlines the gradual shift towards advanced clinical data management. Reports suggest that an esteemed biopharma transferred 25 studies recently, displaying a tangible inclination towards Vault EDC for bolstered efficiency and agility.
According to Veeva, Vault EDC is expected to simplify intricate data management processes, enabling expedited study construction and streamlined workflows. The implementation has already facilitated research entities, sponsors, and CROs in halving their efforts and significantly hastening study execution by 50%.
Acknowledging the superior user experience offered by Veeva Vault EDC for research sites, essential procedures are now streamlined to focus on patient care. The management also alluded that sponsors utilizing Vault EDC can promptly generate and disseminate documents at the end of the trial, propelling study conclusion processes.
Outlook for the Industry
A report by Introspective Market Research foresees the global clinical data management system market rising from $2.3 billion in 2022 to $5.42 billion by 2030, recording an 11.3% CAGR. An upsurge in clinical trials and integration with other healthcare technologies are forecasted to be the propelling forces behind this growth trajectory.
Given the promising market potential, the recent spike in product adoption is poised to steer Veeva Systems’ global operations towards prosperity.
Noteworthy Advancements
In its fourth-quarter fiscal 2024 results announcement, Veeva Systems reported a rise in overall revenue and adjusted earnings per share. Both business segments exhibited robust performance in this period.
Boehringer Ingelheim’s selection of Veeva Vault Clinical and Veeva Vault RIM applications as the technological foundation for clinical and regulatory management in its animal health division was another strategic move by Veeva Systems.
Price Movement
Over the past year, company shares have surged by 29.2%, contrasting with the industry’s 66.4% and the S&P 500’s 31.4% inclines.
Image Source: Zacks Investment Research
Zacks Rank & Other Top Picks
Veeva Systems currently holds a Zacks Rank #1 (Strong Buy).
Other prominent stocks in the broader medical domain include DaVita Inc. (DVA), Cardinal Health, Inc. (CAH), and Cencora, Inc. (COR).
DaVita, flaunting a Zacks Rank #1, boasts an estimated long-term growth rate of 12.1%.
Cardinal Health is currently rated as a Buy (Zacks Rank 2) with an estimated long-term growth rate of 14.2%.
Cencora stands at a Zacks Rank 2 currently and anticipates a long-term growth rate of 9.8%.
This zestful surge in adoption for Veeva Systems promises to usher in a new era of technological prowess, fueling optimism in the medical sector.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
